Keros Therapeutics, Inc. (NASDAQ:KROS)’s stock price gapped up before the market opened on Monday . The stock had previously closed at $33.00, but opened at $34.87. Keros Therapeutics shares last traded at $38.45, with a volume of 13,586 shares.
Several research firms recently commented on KROS. HC Wainwright reissued a “buy” rating and set a $100.00 price target on shares of Keros Therapeutics in a research report on Monday, August 9th. Jefferies Financial Group reissued a “buy” rating and set a $70.00 price target on shares of Keros Therapeutics in a research report on Wednesday, June 23rd. Zacks Investment Research raised Keros Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 7th. SVB Leerink reaffirmed a “buy” rating on shares of Keros Therapeutics in a research report on Sunday, June 27th. Finally, Piper Sandler cut their target price on Keros Therapeutics from $95.00 to $90.00 and set an “overweight” rating on the stock in a research report on Friday, August 6th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Keros Therapeutics currently has an average rating of “Buy” and an average target price of $85.00.
The stock has a market capitalization of $954.76 million, a P/E ratio of -13.52 and a beta of 2.60. The stock has a 50 day moving average of $33.97 and a 200 day moving average of $46.49.
In other news, Director Julius Knowles sold 23,834 shares of the stock in a transaction on Thursday, July 1st. The stock was sold at an average price of $41.28, for a total value of $983,867.52. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 36.10% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in KROS. Zurcher Kantonalbank Zurich Cantonalbank purchased a new stake in shares of Keros Therapeutics during the first quarter valued at $50,000. Ayalon Holdings Ltd. purchased a new stake in Keros Therapeutics in the 2nd quarter worth about $70,000. Royal Bank of Canada lifted its stake in Keros Therapeutics by 187.7% in the 1st quarter. Royal Bank of Canada now owns 1,283 shares of the company’s stock worth $79,000 after acquiring an additional 837 shares in the last quarter. E Fund Management Co. Ltd. purchased a new stake in Keros Therapeutics in the 1st quarter worth about $87,000. Finally, SG Americas Securities LLC purchased a new stake in Keros Therapeutics in the 1st quarter worth about $168,000. 60.48% of the stock is owned by institutional investors and hedge funds.
About Keros Therapeutics (NASDAQ:KROS)
Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.
Recommended Story: Why do corrections happen?
Receive News & Ratings for Keros Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keros Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.